Bioventix reported full-year results in line with expectations, although 4% (£0.3m) higher than expected revenues were offset by higher costs. A 47p special dividend was proposed, resulting in full-year dividend of 120p, up 3%. Strong underlying revenue growth (c.16%), which excludes c.£0.8m of backdated royalties, supported by evidence of early sales traction of troponin, provides a solid base for future growth. We have made minor changes to FY 2020 forecasts as well as introduci
21 Oct 2019
FY 2019 results – signs of troponin progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY 2019 results – signs of troponin progress
Bioventix Plc (BVXP:LON) | 4,600 0 0.0% | Mkt Cap: 240.1m
- Published:
21 Oct 2019 -
Author:
Mark Brewer -
Pages:
16
Bioventix reported full-year results in line with expectations, although 4% (£0.3m) higher than expected revenues were offset by higher costs. A 47p special dividend was proposed, resulting in full-year dividend of 120p, up 3%. Strong underlying revenue growth (c.16%), which excludes c.£0.8m of backdated royalties, supported by evidence of early sales traction of troponin, provides a solid base for future growth. We have made minor changes to FY 2020 forecasts as well as introduci